Terminated NA INTERVENTIONAL 1-arm NCT00363467

Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

A Pilot Study of Intravenous, Targeted-Dose Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk AML

Sponsor: ESP Pharma

Conditions Acute Myeloid Leukemia (AML)

Interventions Busulfan G-CSF Leukapheresis Stem cell reinfusion

Updated 6 times since 2017 Last updated: Feb 20, 2017 Started: May 31, 2006 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other Acute Myeloid Leukemia (AML) trials with similar outcome

Browse all Acute Myeloid Leukemia (AML) trials

Listed as NCT00363467, this NA trial focuses on Acute Myeloid Leukemia (AML) and remains terminated or withdrawn. Sponsored by ESP Pharma, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Dec 2021 — Jul 2024 [monthly]

Terminated NA
Jan 2021 — Dec 2021 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated NA

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ESP Pharma
H. Lee Moffitt Cancer Center and Research Institute

Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States